Protalix Biotherapeutics (PLX)

Dec 23, 2024, 6:50 AM EST - 25 days ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 9, 2024, 6:30 AM EST - 5 weeks ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Nov 14, 2024, 11:23 AM EST - 2 months ago

Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:50 AM EST - 2 months ago

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Nov 7, 2024, 6:50 AM EST - 2 months ago

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Oct 25, 2024, 7:18 AM EDT - 3 months ago

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Sep 17, 2024, 8:00 AM EDT - 4 months ago

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Sep 16, 2024, 8:35 AM EDT - 4 months ago

Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024

Sep 4, 2024, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 6:50 AM EDT - 4 months ago

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Aug 14, 2024, 10:32 AM EDT - 5 months ago

Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 6:50 AM EDT - 5 months ago

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Aug 7, 2024, 6:50 AM EDT - 5 months ago

Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

Jun 13, 2024, 6:50 AM EDT - 7 months ago

Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout

May 29, 2024, 8:38 AM EDT - 8 months ago

Protalix BioTherapeutics to Present at the 2024 BIO International Convention

May 10, 2024, 11:13 AM EDT - 9 months ago

Protalix BioTherapeutics, Inc. (PLX) Q1 2024 Earnings Call Transcript

May 10, 2024, 6:50 AM EDT - 9 months ago

Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

May 3, 2024, 6:50 AM EDT - 9 months ago

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Mar 14, 2024, 1:02 PM EDT - 11 months ago

Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 6:50 AM EDT - 11 months ago

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Mar 7, 2024, 6:50 AM EST - 11 months ago

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Feb 23, 2024, 6:50 AM EST - 11 months ago

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Dec 26, 2023, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Nov 6, 2023, 11:57 AM EST - 1 year ago

Protalix Biotherapeutics, Inc. (PLX) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Oct 30, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

Oct 9, 2023, 8:53 AM EDT - 1 year ago

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

CGEN KMDA TARO TEVA

Oct 9, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel

Sep 12, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

IMTX

Sep 6, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 7, 2023, 10:10 AM EDT - 1 year ago

Protalix Biotherapeutics, Inc. (PLX) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Aug 1, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 31, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023

Jun 8, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

May 30, 2023, 7:01 AM EDT - 1 year ago

Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive Profitability

May 30, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Issues Letter to Stockholders

May 23, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics set to join Russell 3000® Index

May 18, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

May 10, 2023, 6:00 AM EDT - 1 year ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

May 5, 2023, 6:46 AM EDT - 1 year ago

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

May 4, 2023, 12:55 PM EDT - 1 year ago

Protalix Biotherapeutics, Inc. (PLX) Q1 2023 Earnings Call Transcript

May 4, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results

Apr 27, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023

Mar 21, 2023, 6:50 AM EDT - 1 year ago

Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

Mar 13, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank

Feb 27, 2023, 11:10 AM EST - 2 years ago

Protalix BioTherapeutics (PLX) Q4 2022 Earnings Call Transcript

Feb 27, 2023, 6:30 AM EST - 2 years ago

Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

Feb 26, 2023, 6:52 AM EST - 2 years ago

Protalix Undervalued On CHMP Recommendation Of PRX-102 For Fabry Disease